权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Heart Failure Polypill in India: A Late-Stage Implementation Strategy

印度的心力衰竭复方药物：后期实施策略

基本信息

批准号：
10371464
负责人：
ANUBHA AGARWAL
金额：
$ 14.76万
依托单位：
WASHINGTON UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-09-23 至 2024-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10371464
关键词：
Adherence Adopted Adrenergic beta-Antagonists Adult Adverse event Age Angiotensin Receptor Area Australia Cardiomyopathies Cardiovascular Diseases Cardiovascular system Caring Chronic Chronic Disease Cities Clinical Clinical Pharmacology Clinical Trials Clinical Trials Design Collaborations Consensus Consolidated Framework for Implementation Research Country Data Collection Developing Countries Development Disease Disease Marker EFRAC Ensure Evaluation Focus Groups Funding Future Global Change Goals Guidelines HIV Health Personnel Heart Heart failure Hospitalization Hospitals Hybrids Hypertension Income India Individual Institutes Interruption Intervention Investments Kansas Left Ventricular Ejection Fraction Measures Medical Mentorship Methodology Methods Mineralocorticoid Receptor Morbidity - disease rate National Heart, Lung, and Blood Institute Natriuretic Peptides New York Outcome Participant Patient Care Patients Pharmaceutical Preparations Pharmacotherapy Phase Positioning Attribute Prevalence Process Public Health Questionnaires Randomized Clinical Trials Reach Effectiveness Adoption Implementation and Maintenance Registries Reporting Research Research Methodology Risk Factors Safety Science Series Serious Adverse Event Severity of illness Strategic vision Target Populations Time Titrations Training Training Activity Translating Treatment Failure United States United States National Institutes of Health Universities Withdrawal antagonist base burden of illness career design disorder control evidence base global health health related quality of life implementation barriers implementation evaluation implementation outcomes implementation science implementation strategy improved innovation low and middle-income countries medication compliance meetings mortality multidisciplinary novel novel strategies primary outcome process evaluation research and development secondary outcome sex socioeconomics success treatment as usual trial design

项目摘要

PROJECT SUMMARY/ABSTRACT Heart failure (HF) is a leading global public health problem. The burden of HF is increasing in low- and middle- income countries and clinical outcomes remain poor. Guideline-directed medical therapy (a combination of distinct medications from disparate drug classes) improves morbidity and mortality in patients with HF with reduced ejection fraction (HFrEF). Despite this high-quality evidence, guideline-directed medical therapy remains widely underutilized globally and specifically in India. This gap represents a key target for intervention to save lives. Dr. Agarwal’s K99/R00 proposal aims to substantially simplify HF management by shifting the treatment paradigm for undertreated patients with HFrEF from multi-drug therapy with sequential initiation and titration to a novel late-stage implementation strategy of a HFrEF polypill of guideline-directed medical therapy including a beta-blocker, angiotensin receptor blocker, and mineralocorticoid receptor antagonist. First, Dr. Agarwal will conduct formative mixed methods research including a HF treatment consensus meeting and focus group discussions to guide development of the HFrEF polypill-based strategy in India. Second, she will evaluate whether, compared to usual care, a HFrEF polypill implementation strategy will reduce cardiovascular disease mortality and HF hospitalizations at 12 months in adults with HFrEF in India using a multi-center, type I hybrid randomized clinical trial design. She will also assess the effect of the HFrEF polypill implementation strategy on important secondary outcomes including medication adherence, markers of HF disease severity, health-related quality of life, and safety measured by adverse events. Finally, Dr. Agarwal will apply methods of process evaluation to assess implementation outcomes of the HFrEF polypill in India, a key step in translating evidence generated into broader use globally. The K99 phase will also provide essential methodological training for Dr. Agarwal to transition to research independence in the R00 phase. Dr. Agarwal proposes training in 1) implementation science methods, 2) clinical trial methods including innovative platform trial designs, and 3) regulatory science for global pharmacological clinical trials. This K99 training will prepare her to be a leading clinical trialist in global heart failure implementation science. Dr. Agarwal’s global mentorship team is led by Dr. Mark Huffman (Northwestern University, US), with key co-mentorship provided by experts in cardiovascular clinical trials in low- and middle-income countries, Drs. Dorairaj Prabhakaran (Centre for Chronic Disease Control, India) and Anushka Patel (The George Institute for Global Health, Australia). This mentorship team, supported by key collaborators (Drs. Hirschhorn, Mohanan, Ciolino) and advisors (Drs. Yancy, Lloyd-Jones), will ensure scientific success and oversee the candidate’s advanced training in their relative areas of expertise. This K99/R00 proposal supports Dr. Agarwal’s transition to launch an independent career as a future leader in global, late-stage translational cardiovascular research. Importantly, this proposal has the potential to transform HF care through simplified care in India and other settings, including in the United States.

项目总结/文摘